Literature DB >> 30145772

Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide.

Hortensia Álvarez1, Ana Mariño2, Nieves Valcarce3, Jesús García-González4, Helena Díaz-Cambre5, Josep M Llibre6.   

Abstract

INTRODUCTION: Data are lacking regarding overdose of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF).
MATERIAL AND METHODS: We present the first report of suicidal attempt with E/C/F/TAF in a Human Immunodeficiency Virus-infected subject.
RESULTS: A reversible acute renal failure with no proximal tubulopathy and neuropsychiatric issues are discussed. E/C/F/TAF withdrawal resulted in favourable renal and neuropsychiatric outcomes. The suicide attempt seemed unrelated to the integrase strand transfer inhibitor, being evenly explained within the context of stressful personal conflicts.
CONCLUSION: A suicidal attempt with an E/C/F/TAF overdose in an HIV-infected patient, resulted in a favourable outcome from a renal and neuropsychiatric standpoint.

Entities:  

Keywords:  Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide; Overdose; Suicide attempt

Mesh:

Substances:

Year:  2018        PMID: 30145772     DOI: 10.1007/s15010-018-1201-x

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  16 in total

1.  A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results.

Authors:  David A Wohl; Calvin Cohen; Joel E Gallant; Anthony Mills; Paul E Sax; Edwin Dejesus; Andrew Zolopa; Hui C Liu; Andrew Plummer; Kirsten L White; Andrew K Cheng; Martin S Rhee; Javier Szwarcberg
Journal:  J Acquir Immune Defic Syndr       Date:  2014-03-01       Impact factor: 3.731

Review 2.  Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity.

Authors:  Jean C Yombi; Anton Pozniak; Marta Boffito; Rachael Jones; Saye Khoo; Jeremy Levy; Frank A Post
Journal:  AIDS       Date:  2014-03-13       Impact factor: 4.177

3.  Assessment of suicidal intention: the Scale for Suicide Ideation.

Authors:  A T Beck; M Kovacs; A Weissman
Journal:  J Consult Clin Psychol       Date:  1979-04

4.  In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.

Authors:  Christian Callebaut; George Stepan; Yang Tian; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2015-07-06       Impact factor: 5.191

5.  Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.

Authors:  Aditya H Gaur; Hilda Kizito; Wasana Prasitsueubsai; Natella Rakhmanina; Mohammed Rassool; Rana Chakraborty; Jagmohan Batra; Pope Kosalaraksa; Wicharn Luesomboon; Danielle Porter; Yongwu Shao; Michael Myers; Lillian Ting; Devi SenGupta; Erin Quirk; Martin S Rhee
Journal:  Lancet HIV       Date:  2016-10-17       Impact factor: 12.767

6.  Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI.

Authors:  Anton Pozniak; Jason Flamm; Andrea Antinori; Mark Bloch; Douglas Ward; Juan Berenguer; Pierre Cote; Kristen Andreatta; William Garner; Javier Szwarcberg; Thai Nguyen-Cleary; Damian J McColl; David Piontkowsky
Journal:  HIV Clin Trials       Date:  2017-07-09

7.  Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.

Authors:  José R Arribas; Melanie Thompson; Paul E Sax; Bernhard Haas; Cheryl McDonald; David A Wohl; Edwin DeJesus; Amanda E Clarke; Susan Guo; Hui Wang; Christian Callebaut; Andrew Plummer; Andrew Cheng; Moupali Das; Scott McCallister
Journal:  J Acquir Immune Defic Syndr       Date:  2017-06-01       Impact factor: 3.731

8.  Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults.

Authors:  Joel Gallant; Jason Brunetta; Gordon Crofoot; Paul Benson; Anthony Mills; Cynthia Brinson; Shinichi Oka; Andrew Cheng; Will Garner; Marshall Fordyce; Moupali Das; Scott McCallister
Journal:  J Acquir Immune Defic Syndr       Date:  2016-11-01       Impact factor: 3.731

9.  Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.

Authors:  Frank A Post; Pablo Tebas; Amanda Clarke; Laurent Cotte; William R Short; Michael E Abram; Shuping Jiang; Andrew Cheng; Moupali Das; Marshall W Fordyce
Journal:  J Acquir Immune Defic Syndr       Date:  2017-02-01       Impact factor: 3.731

10.  Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study.

Authors:  Anthony Mills; Jose R Arribas; Jaime Andrade-Villanueva; Giovanni DiPerri; Jan Van Lunzen; Ellen Koenig; Richard Elion; Matthias Cavassini; Jose Valdez Madruga; Jason Brunetta; David Shamblaw; Edwin DeJesus; Chloe Orkin; David A Wohl; Indira Brar; Jeffrey L Stephens; Pierre-Marie Girard; Gregory Huhn; Andrew Plummer; Ya-Pei Liu; Andrew K Cheng; Scott McCallister
Journal:  Lancet Infect Dis       Date:  2015-11-02       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.